Sökning: onr:"swepub:oai:DiVA.org:uu-73118" >
Treatment with irbe...
Treatment with irbesartan or atenolol improves endothelial function in essential hypertension
-
- von zur Mühlen, Bengt (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Akut- och internmedicin
-
- Kahan, Thomas (författare)
- Karolinska Institutet
-
- Hägg, Anders (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Akut- och internmedicin
-
visa fler...
-
- Millgård, Jonas (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Akut- och internmedicin
-
- Lind, Lars (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Akut- och internmedicin
-
visa färre...
-
(creator_code:org_t)
- Ovid Technologies (Wolters Kluwer Health), 2001
- 2001
- Engelska.
-
Ingår i: Journal of Hypertension. - : Ovid Technologies (Wolters Kluwer Health). - 0263-6352 .- 1473-5598. ; 19:10, s. 1813-1818
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- OBJECTIVES: To investigate if antihypertensive treatment could improve endothelium-dependent vasodilatation in hypertensive patients, and whether the angiotensin II subtype-1 (AT1)-receptor antagonist irbesartan and the beta1-receptor antagonist atenolol would differ in this respect. SUBJECTS AND METHODS: Thirty-four patients (28 men and six women) with mild-to-moderate essential hypertension (diastolic blood pressure 90-120 mmHg) were randomized to once daily 150-300 mg irbesartan or 50-100 mg atenolol in a double-blind fashion, preceded by a placebo run-in period. Forearm blood flow (FBF) was assessed by venous occlusion plethysmography during local intra-arterial infusions of methacholine and sodium nitroprusside, to evaluate endothelium-dependent and endothelium-independent vasodilatation, respectively. Measurements of FBF were undertaken at the end of the run-in placebo period and repeated after 3 months of active antihypertensive treatment. RESULTS: Irbesartan and atenolol induced a similar decline in blood pressure (from 171/107 to 158/98 mmHg, P < 0.05), and improved endothelium-dependent vasodilatation (e.g. an increase in FBF response to 4 microg/min methacholine from 325 +/- 29% to 411 +/- 41%, P < 0.05), with no difference between the two study drugs. No significant changes in endothelium-independent vasodilatation were induced by irbesartan or by atenolol. CONCLUSIONS: The present study shows that 3 months of antihypertensive therapy with irbesartan or atenolol improves endothelium-dependent vasodilatation.
Nyckelord
- Adrenergic beta-Antagonists/*therapeutic use
- Antihypertensive Agents/*therapeutic use
- Atenolol/*therapeutic use
- Biphenyl Compounds/*therapeutic use
- Double-Blind Method
- Endothelium; Vascular/*drug effects/*physiopathology
- Female
- Forearm/blood supply
- Humans
- Hypertension/*drug therapy/*physiopathology
- Male
- Middle Aged
- Receptor; Angiotensin; Type 1
- Receptors; Angiotensin/antagonists & inhibitors
- Regional Blood Flow/drug effects
- Research Support; Non-U.S. Gov't
- Tetrazoles/*therapeutic use
- Vasodilation/drug effects
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- vet (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas